M
Middle East Pharmaceutical Industries Company SJSC
SAU:4016
Middle East Pharmaceutical Industries Company SJSC
SAU:4016
Price:
121.2
SAR
1.68%
Market Cap:
2.4B
SAR
Income Statement
Earnings Waterfall
Middle East Pharmaceutical Industries Company SJSC
Middle East Pharmaceutical Industries Company SJSC
|
Revenue
|
394m
SAR
|
|
Cost of Revenue
|
-150.6m
SAR
|
|
Gross Profit
|
243.4m
SAR
|
|
Operating Expenses
|
-152.3m
SAR
|
|
Operating Income
|
91m
SAR
|
|
Other Expenses
|
-11.2m
SAR
|
|
Net Income
|
79.8m
SAR
|
Income Statement
Middle East Pharmaceutical Industries Company SJSC
Middle East Pharmaceutical Industries Company SJSC
Currency: SAR
Millions
TTM
| Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | ||
|---|---|---|---|---|---|---|
| Revenue | ||||||
| Revenue |
338
N/A
|
508
+50%
|
515
+2%
|
596
+16%
|
394
-34%
|
|
| Gross Profit | ||||||
| Cost of Revenue |
(134)
|
(201)
|
(197)
|
(232)
|
(151)
|
|
| Gross Profit |
204
N/A
|
306
+50%
|
318
+4%
|
365
+15%
|
243
-33%
|
|
| Operating Income | ||||||
| Operating Expenses |
(126)
|
(195)
|
(203)
|
(243)
|
(152)
|
|
| Selling, General & Administrative |
(121)
|
(183)
|
(190)
|
(228)
|
(149)
|
|
| Depreciation & Amortization |
(4)
|
(12)
|
(12)
|
(15)
|
(5)
|
|
| Other Operating Expenses |
(0)
|
(1)
|
(1)
|
(0)
|
1
|
|
| Operating Income |
78
N/A
|
111
+42%
|
115
+3%
|
122
+6%
|
91
-25%
|
|
| Pre-Tax Income | ||||||
| Interest Income Expense |
(6)
|
(8)
|
(8)
|
(8)
|
(4)
|
|
| Total Other Income |
(1)
|
(2)
|
(2)
|
(2)
|
(1)
|
|
| Pre-Tax Income |
71
N/A
|
102
+43%
|
106
+4%
|
111
+5%
|
86
-22%
|
|
| Net Income | ||||||
| Tax Provision |
(6)
|
(9)
|
(9)
|
(10)
|
(7)
|
|
| Income from Continuing Operations |
66
|
93
|
97
|
101
|
80
|
|
| Net Income (Common) |
66
N/A
|
93
+42%
|
97
+4%
|
101
+4%
|
80
-21%
|
|
| EPS (Diluted) |
3.29
N/A
|
4.66
+42%
|
4.85
+4%
|
5.04
+4%
|
3.99
-21%
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
